MX2021000966A - Piridopirimidinas como inhibidores del receptor de histamina h4. - Google Patents

Piridopirimidinas como inhibidores del receptor de histamina h4.

Info

Publication number
MX2021000966A
MX2021000966A MX2021000966A MX2021000966A MX2021000966A MX 2021000966 A MX2021000966 A MX 2021000966A MX 2021000966 A MX2021000966 A MX 2021000966A MX 2021000966 A MX2021000966 A MX 2021000966A MX 2021000966 A MX2021000966 A MX 2021000966A
Authority
MX
Mexico
Prior art keywords
histamine
pyridopyrimidines
receptor inhibitors
receptor
solvates
Prior art date
Application number
MX2021000966A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernandez
Tizne Roberto Olivera
Domínguez Neftalí García
Arce Arturo Zazpe
Cerdeiras Paloma Tato
Pedro Bárbara Noverges
Vivar Reyes Corcóstegui
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MX2021000966A publication Critical patent/MX2021000966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I): (ver Fórmula) o a sales o solvatos farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento y/o la prevención de enfermedades o trastornos mediados por el receptor de histamina H4.
MX2021000966A 2018-07-25 2019-07-24 Piridopirimidinas como inhibidores del receptor de histamina h4. MX2021000966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25
PCT/EP2019/069905 WO2020020939A1 (en) 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors

Publications (1)

Publication Number Publication Date
MX2021000966A true MX2021000966A (es) 2021-07-06

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000966A MX2021000966A (es) 2018-07-25 2019-07-24 Piridopirimidinas como inhibidores del receptor de histamina h4.

Country Status (28)

Country Link
US (1) US20210300922A1 (es)
EP (1) EP3827005B1 (es)
JP (1) JP7093462B2 (es)
KR (1) KR102603203B1 (es)
CN (1) CN112739699B (es)
AU (1) AU2019310889B2 (es)
BR (1) BR112021001270A2 (es)
CA (1) CA3107556C (es)
CL (1) CL2021000184A1 (es)
CO (1) CO2021001925A2 (es)
DK (1) DK3827005T3 (es)
EA (1) EA202190339A1 (es)
EC (1) ECSP21010874A (es)
ES (1) ES2929227T3 (es)
HR (1) HRP20221250T1 (es)
HU (1) HUE059824T2 (es)
LT (1) LT3827005T (es)
MA (1) MA53372B1 (es)
MX (1) MX2021000966A (es)
PE (1) PE20211638A1 (es)
PH (1) PH12021550143A1 (es)
PL (1) PL3827005T3 (es)
PT (1) PT3827005T (es)
RS (1) RS63661B1 (es)
SA (1) SA521421098B1 (es)
SG (1) SG11202100575QA (es)
WO (1) WO2020020939A1 (es)
ZA (1) ZA202101092B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534434A (ja) * 2019-05-31 2022-07-29 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
JP2023084709A (ja) * 2020-04-28 2023-06-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ヒスタミンｈ４受容体調節作用を有する新規二環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
EP2077263A1 (en) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
MX2011003447A (es) * 2008-09-30 2011-07-29 Astrazeneca Ab Inhibidores heterociclicos de jak quinasa.
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
CN105102456B (zh) * 2012-09-28 2017-11-14 癌症研究技术有限公司 非典型蛋白激酶c的氮杂喹唑啉抑制剂

Also Published As

Publication number Publication date
AU2019310889A1 (en) 2021-03-11
MA53372B1 (fr) 2022-10-31
CN112739699B (zh) 2023-11-28
PH12021550143A1 (en) 2021-09-13
DK3827005T3 (da) 2022-09-19
ECSP21010874A (es) 2021-03-31
PE20211638A1 (es) 2021-08-24
NZ773053A (en) 2023-10-27
WO2020020939A1 (en) 2020-01-30
CN112739699A (zh) 2021-04-30
SA521421098B1 (ar) 2024-02-08
CA3107556C (en) 2022-10-25
US20210300922A1 (en) 2021-09-30
ZA202101092B (en) 2022-09-28
LT3827005T (lt) 2022-11-10
PT3827005T (pt) 2022-11-04
KR102603203B1 (ko) 2023-11-16
EP3827005A1 (en) 2021-06-02
CO2021001925A2 (es) 2021-03-08
JP2021531304A (ja) 2021-11-18
AU2019310889B2 (en) 2022-03-31
CL2021000184A1 (es) 2021-07-09
ES2929227T3 (es) 2022-11-25
PL3827005T3 (pl) 2022-11-28
MA53372A (fr) 2021-06-02
EP3827005B1 (en) 2022-08-17
EA202190339A1 (ru) 2021-05-20
JP7093462B2 (ja) 2022-06-29
BR112021001270A2 (pt) 2021-04-20
CA3107556A1 (en) 2020-01-30
HRP20221250T1 (hr) 2022-12-09
KR20210038909A (ko) 2021-04-08
RS63661B1 (sr) 2022-11-30
SG11202100575QA (en) 2021-02-25
HUE059824T2 (hu) 2023-01-28

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
WO2016109217A3 (en) Btk inhibitors
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX371102B (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2024000043A (es) Compuestos inhibidores de la caspasa-2.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12017501736A1 (en) Indole derivatives
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.